INKON Life(SZ:300143) 光大证券研究·2025-11-04 23:05Core Viewpoint - The company achieved a revenue of 1.358 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 10.59%, and a net profit attributable to shareholders of 87 million yuan, up 5.20% year-on-year, indicating that the performance is generally in line with expectations [4]. Group 1: Medical Services Sector - The medical services segment continued its growth momentum, with self-operated hospital user numbers increasing by 8% year-on-year, inpatient visits rising by 20%, and surgical volume growing by 10%, with tertiary surgeries up by 12% [5]. - The oncology business is a core driver for the company, generating revenue of 415 million yuan in the first three quarters of 2025, showing significant year-on-year growth [5]. - The overall expense ratio decreased by 0.3 percentage points year-on-year, reflecting initial improvements in quality and efficiency [5]. - The company is actively embracing AI capabilities, enhancing diagnostic efficiency and service experience, achieving a patient net promoter score (NPS) of 92.5% [5]. Group 2: Medical Devices Sector - In the medical devices segment, domestic market growth was driven by high-end product and channel upgrades, maintaining a stable market share [6]. - The overseas market emerged as a significant growth engine, with overseas revenue from medical devices increasing by 29% year-on-year in the first three quarters of 2025 [6]. - However, the tightening of funds among downstream hospital clients has extended the payment cycle for large equipment, leading the company to recognize credit impairment losses on related accounts receivable, which pressured current profits [6]. Group 3: Strategic Acquisitions - The acquisition of Changsha Kexin Tumor Hospital, a comprehensive tertiary tumor specialty hospital, is expected to synergize with existing hospitals in Sichuan, Suzhou, and Chongqing, further deepening the company's strategic development [7]. - Following the acquisition, patient volume at Changsha Kexin increased by 11% year-on-year, with outpatient visits also up by 11%, and inpatient volume rising by 13% due to enhanced operational efficiency through AI capabilities [7].